•  
  •  
  •  
  •  

2026-08-06 05:24:00

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore

Keywords Selected:  Lupin

Research

  • Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD

Stock Report

  • Lupin Announces the Approval of Diazepam Injection, USP in the United States
  • Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection
  • Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy
  • Lupin Named Among World's Most Sustainable Companies by TIME and Statista
  • Lupin Receives EIR from U.S. FDA for its Somerset Facility with VAI Classification
  • Lupin announces EMA Approval for NaMuscla® Expansion for Pediatric Indication with New Strengths
  • Lupin receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
  • Lupin Launches Azilsartan Medoxomil Tablets in the United States
  • Lupin Collaborates with ERN for Luforbec® (beclometasone/formoterol) pMDI Launch in Spain
  • Lupin receives approval from U.S. FDA for Ranluspec™ (ranibizumab) Injection
  • NATCO and Lupin receive approval from U.S. FDA for Eribulin Mesylate Injection
  • Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
  • Lupin's Ankleshwar Facility Receives EIR from U.S. FDA
  • Lupin receives China Approval for Oseltamivir Phosphate Oral Suspension
  • Lupin Receives U.S. FDA Approval for Famotidine Injection, USP
  • Lupin Ltd recommends dividend of Rs. 18
  • Lupin Ltd posts Q4FY26 consolidated PAT climbs to Rs. 1460.34 crores
  • Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid
  • Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • USFDA inspection at Somerset facility of Lupin Ltd
  • Lupin Pharmaceuticals, Inc, USA enters into settlement agreement with Humana Inc
  • Lupin Launches Dapagliflozin Tablets in the United States
  • Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • Lupin Announces the Approval of Dapagliflozin Tablets in the United States

Latest Post

  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025